All Eyes on Kenvue’s Post-IPO Results for Market Sentiment Signs

The year’s biggest IPO is due for its first earnings check-up, which Wall Street sees as a crucial update for newly public companies in a tepid market.

Kenvue Inc. will post results Thursday, the first of that cohort, after the maker of Tylenol and Listerine raised $4.4 billion in May as the consumer health products spinoff of Johnson & Johnson. Its report, paired with earnings from Mexican industrial real estate developer Corporacion Inmobiliaria Vesta SAB, which recently debuted in the US, may be under the microscope for investors who have snapped up their shares.

“Anything earnings related is going ...